MCID: HYP025
MIFTS: 47

Hyperphosphatemia

Categories: Metabolic diseases

Aliases & Classifications for Hyperphosphatemia

MalaCards integrated aliases for Hyperphosphatemia:

Name: Hyperphosphatemia 12 29 55 44 15 72

Classifications:



External Ids:

Disease Ontology 12 DOID:0050459
MeSH 44 D054559
NCIt 50 C113750
SNOMED-CT 68 20165001
UMLS 72 C0085681

Summaries for Hyperphosphatemia

Disease Ontology : 12 A phosphorus metabolism disease characterized by hyperphosphatemia and abnormal deposits of phosphate and calcium in joints and soft tissues, results from abnomral phosphorus metabolism and has material basis in mutations in the FGF23, GALNT3 or KL gene.

MalaCards based summary : Hyperphosphatemia is related to tumoral calcinosis, hyperphosphatemic, familial, 1 and pseudohypoparathyroidism. An important gene associated with Hyperphosphatemia is FGF23 (Fibroblast Growth Factor 23), and among its related pathways/superpathways are Signaling by FGFR2 and Endochondral Ossification. The drugs Alendronate and Atorvastatin have been mentioned in the context of this disorder. Affiliated tissues include kidney, bone and smooth muscle, and related phenotypes are growth/size/body region and homeostasis/metabolism

Wikipedia : 75 Hyperphosphatemia is an electrolyte disorder in which there is an elevated level of phosphate in the... more...

Related Diseases for Hyperphosphatemia

Diseases related to Hyperphosphatemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 180)
# Related Disease Score Top Affiliating Genes
1 tumoral calcinosis, hyperphosphatemic, familial, 1 34.3 KL GALNT3 FGF23
2 pseudohypoparathyroidism 32.6 STX16 PTH GNAS
3 pseudohypoparathyroidism, type ib 32.5 STX16 PTH GNAS
4 familial tumoral calcinosis 32.4 PHEX KL GALNT3 FGF23
5 hypoparathyroidism, familial isolated 31.5 PTH GCM2 CASR
6 hypoparathyroidism 31.5 PTH GCM2 FGF23 CASR
7 hyperostosis 31.1 KL GALNT3 FGF23
8 hypophosphatemia 30.5 SLC34A1 PTH PHEX FGF23
9 oncogenic osteomalacia 30.4 PTH PHEX FGF23
10 hypophosphatemic rickets, autosomal dominant 30.1 PHEX GALNT3 FGF23
11 hypocalcemia, autosomal dominant 1 30.1 VDR PTH GNAS GCM2 FGF23 CASR
12 calcinosis 30.0 PHEX MGP KL GALNT3 FGF23
13 uremia 29.9 VDR PTH CASR
14 renal osteodystrophy 29.8 VDR PTH FGF23 CASR
15 hypophosphatasia 29.7 RUNX2 PHEX
16 hypophosphatemic rickets, x-linked recessive 29.7 VDR SLC34A1 PHEX FGF23
17 osteitis fibrosa 29.5 PTH GNAS CASR
18 kidney disease 29.5 VDR PTH MGP FGF23 CASR
19 hypophosphatemic rickets, x-linked dominant 29.5 SLC34A1 PTH PHEX KL FGF23
20 bone resorption disease 29.4 VDR RUNX2 PTH
21 rickets 29.4 VDR SLC34A1 PTH PHEX FGF23
22 calciphylaxis 29.3 VDR PTH FGF23 CASR
23 hypervitaminosis d 29.2 VDR PTH KL GALNT3 FGF23
24 hyperparathyroidism 29.2 VDR PTH PHEX GCM2 FGF23 CASR
25 bone disease 29.0 VDR RUNX2 PTH FGF23 CASR
26 osteomalacia 28.9 VDR PTH PHEX FGF23 CASR
27 secondary hyperparathyroidism of renal origin 28.9 VDR PTH FGF23 CASR
28 nephrocalcinosis 28.7 SLC34A1 PTH PHEX CASR
29 primary hyperparathyroidism 28.3 VDR PTH GCM2 FGF23 CASR
30 osteoporosis 26.2 VDR SLC34A1 RUNX2 PTH MGP KL
31 hyperphosphatemia, polyuria, and seizures 12.4
32 tumoral calcinosis, hyperphosphatemic, familial, 2 11.7
33 tumoral calcinosis, hyperphosphatemic, familial, 3 11.7
34 pseudohypoparathyroidism, type ia 11.1
35 pseudohypoparathyroidism, type ii 11.1
36 hypoparathyroidism-retardation-dysmorphism syndrome 11.1
37 hypoparathyroidism, x-linked 11.1
38 pseudohypoparathyroidism, type ic 11.1
39 chronic kidney disease 10.8
40 end stage renal failure 10.8
41 arterial calcification, generalized, of infancy, 1 10.7
42 secondary hyperparathyroidism 10.7
43 tracheal calcification 10.5 KL FGF23
44 lymphocytic leukemia 10.5
45 impaired renal function disease 10.4 PTH FGF23
46 leukemia, acute lymphoblastic 10.4
47 hypothyroidism, congenital, nongoitrous, 1 10.4 STX16 GNAS
48 constipation 10.4
49 chief cell adenoma 10.4 PTH GCM2
50 opsismodysplasia 10.4 PHEX FGF23

Graphical network of the top 20 diseases related to Hyperphosphatemia:



Diseases related to Hyperphosphatemia

Symptoms & Phenotypes for Hyperphosphatemia

MGI Mouse Phenotypes related to Hyperphosphatemia:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.26 CASR FGF23 GALNT3 GNAS KL MGP
2 homeostasis/metabolism MP:0005376 10.25 CASR FGF23 GALNT3 GCM2 GNAS KL
3 cardiovascular system MP:0005385 10.2 FGF23 GALNT3 GNAS KL MGP PHEX
4 cellular MP:0005384 10.19 CASR GALNT3 GCM2 GNAS KL PHEX
5 endocrine/exocrine gland MP:0005379 10.19 CASR FGF23 GALNT3 GCM2 GNAS KL
6 craniofacial MP:0005382 10.13 GALNT3 GCM2 GNAS KL PHEX PTH
7 hematopoietic system MP:0005397 10.11 CASR FGF23 GALNT3 GNAS KL PHEX
8 immune system MP:0005387 10.06 CASR FGF23 GALNT3 GNAS KL PHEX
9 digestive/alimentary MP:0005381 10.05 CASR FGF23 GALNT3 KL PHEX RUNX2
10 mortality/aging MP:0010768 10 CASR FGF23 GCM2 GNAS KL MGP
11 limbs/digits/tail MP:0005371 9.92 FGF23 GALNT3 GNAS KL PHEX PTH
12 integument MP:0010771 9.91 CASR FGF23 GALNT3 GNAS KL RUNX2
13 muscle MP:0005369 9.76 CASR GALNT3 GNAS KL MGP RUNX2
14 renal/urinary system MP:0005367 9.65 CASR FGF23 GALNT3 GCM2 GNAS KL
15 skeleton MP:0005390 9.44 CASR FGF23 GALNT3 GCM2 GNAS KL

Drugs & Therapeutics for Hyperphosphatemia

Drugs for Hyperphosphatemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 89)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Alendronate Approved Phase 4 66376-36-1, 121268-17-5 2088
2
Atorvastatin Approved Phase 4 134523-00-5 60823
3
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
4
Calcium carbonate Approved, Investigational Phase 4 471-34-1
5
Sodium citrate Approved, Investigational Phase 4 68-04-2
6
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
7
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 54670067 5785
8
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
9
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 5280453 134070
10 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
11 Liver Extracts Phase 4
12 Anticholesteremic Agents Phase 4
13 Cathartics Phase 4
14 Laxatives Phase 4
15 Cola Phase 4
16 Picosulfate sodium Phase 4
17 Antioxidants Phase 4
18 Protective Agents Phase 4
19 Hematinics Phase 4
20 Ferric Compounds Phase 4
21 Gastrointestinal Agents Phase 4
22 Antacids Phase 4
23 Anti-Ulcer Agents Phase 4
24 Citrate Phase 4
25 Anticoagulants Phase 4
26 Calcium Supplement Phase 4
27 Vasoconstrictor Agents Phase 4
28
carbamide peroxide Approved Phase 3 124-43-6
29
Sevelamer Approved Phase 3 52757-95-6
30
Nicotinamide Approved, Investigational Phase 3 98-92-0 936
31
Iron Approved, Experimental Phase 3 15438-31-0, 7439-89-6 23925 27284
32
Cinacalcet Approved Phase 3 226256-56-0 156419
33
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
34
Niacin Approved, Investigational, Nutraceutical Phase 3 59-67-6 938
35 Chelating Agents Phase 3
36 Lipid Regulating Agents Phase 3
37 Vitamin B9 Phase 3
38 Nicotinic Acids Phase 3
39 Vitamin B3 Phase 3
40 Folate Phase 3
41 Vitamin B Complex Phase 3
42 Hypolipidemic Agents Phase 3
43 Vasodilator Agents Phase 3
44 Antimetabolites Phase 3
45 Bile Acids and Salts Phase 3
46 Hormone Antagonists Phase 3
47 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
48 Pharmaceutical Solutions Phase 3
49 Calcimimetic Agents Phase 3
50
Angiotensin II Approved, Investigational Phase 2 11128-99-7, 68521-88-0, 4474-91-3 172198

Interventional clinical trials:

(show top 50) (show all 181)
# Name Status NCT ID Phase Drugs
1 The Efficacy and Safety of Nicotinic Acid in the Hemodialysis Patients With Hyperphosphatemia Unknown status NCT02836184 Phase 4 Nicotinic Acids;Calcium Carbonate
2 The Effect of Ferric Citrate on Inflammation and Lipid Levels in Patients on Hemodialysis Unknown status NCT02661295 Phase 4 Ferric Citrate
3 Can Alendronate Suppress Aortic and Coronary Artery Calcification and Improve Bone Mineral Density in Chronic Peritoneal Dialysis Patients? Unknown status NCT00299572 Phase 4 alendronate (Fosamax)
4 Long Term Evaluation of Sevelamer HCl vs. Calcium-based Phosphate Binder in the Treatment of Hyperphosphatemia in Hemodialysis Patients Completed NCT01755078 Phase 4 Sevelamer HCl;Calcium-based phosphate binder
5 A Long-Term, Open-Label, Prospective Phase IV Study to Assess the Safety and Efficacy of Nephoxil® in Subjects With End Stage Renal Disease (ESRD) on Dialysis Completed NCT03256838 Phase 4 Ferric Citrate
6 A Phase IV, Open-Label, Multi-Center Trial Evaluating the Efficacy of Fosrenol Compared to Existing Therapy in Adults With End Stage Renal Disease Treated for Hyperphosphatemia Completed NCT00160121 Phase 4 Lanthanum carbonate
7 Phosphate Kinetic Modeling 2 Completed NCT01252771 Phase 4
8 Initial Dosing of Paricalcitol Based on iPTH Parathyroid Hormone Levels in Hemodialysis Patients With Secondary Hyperparathyroidism Completed NCT00307840 Phase 4 paricalcitol
9 CARE-2 (Calcium Acetate (PhosLo®)/Sevelamer(Renagel®) Evaluation Study 2) Completed NCT00211939 Phase 4 calcium acetate;sevelamer;atorvastatin
10 The Study of Efficacy and Safety of Calcium Sensing Receptor in Chronic Dialysis Patients Completed NCT02056730 Phase 4 calcium sensing receptor agonist
11 A Prospective Audit of Tolerability, Mucosal Cleansing Efficacy and Mucosal Abnormalities Associated With Standard Orally Administered Colon Cleansing Preparations for Colonoscopy Completed NCT00750763 Phase 4 Colonlytely;Picolax/Picoprep;Fleet
12 Effect of Vitamin D3 Supplementation on Arterial and Bone Remodeling in Chronic Kidney Disease Patients Recruiting NCT02999204 Phase 4 Vitamin D3
13 Phosphate Lowering to Treat Vascular Dysfunction in Chronic Kidney Disease Recruiting NCT02209636 Phase 4 Lanthanum carbonate;placebo;Ascorbic Acid;Nitroglycerin
14 Transition to Ferric Citrate Among Hemodialysis and Peritoneal Dialysis Patients: A Phase 4 "Real World" Experience Study From Kaiser Permanente Southern California Active, not recruiting NCT03079869 Phase 4 Ferric Citrate
15 Effect of Auryxia on ESA Utilization in ESRD Patients With High Ferritin & Low Transferrin Saturation: A Pilot Project Active, not recruiting NCT03055598 Phase 4 Ferric Citrate
16 Lanthanum Carbonate Versus Calcium Carbonate for Vascular Abnormalities in Patients With Chronic Kidney Disease and Hyperphosphatemia Enrolling by invitation NCT02237534 Phase 4 Lanthanum carbonate;Calcium Carbonate
17 A Long-Term, Open Label Study to Evaluate the Ability of Tenapanor Alone or in Combination With Sevelamer to Treat to Goal Serum Phosphorus in Patients With End-Stage Kidney Disease on Dialysis (NORMALIZE) Enrolling by invitation NCT03988920 Phase 4 Tenapanor;Sevelamer Carbonate
18 The Efficacy and Safety of Niacin on Hyperphosphatemia in End Stage Renal Disease Patients Undergoing Haemodialysis Not yet recruiting NCT03163576 Phase 4 Niacin;Phosphate Binder
19 Effect of Velphoro on Serum Phosphate and Albumin in Peritoneal Dialysis Patients Not yet recruiting NCT04046263 Phase 4 Sucroferric Oxyhydroxide Chewable Tablet
20 CALCIUM CITRATE vs CALCIUM CARBONATE FOR THE MANAGEMENT OF CHRONIC HYPOPARATHYROIDISM Not yet recruiting NCT03425747 Phase 4 Calcium Carbonate;Calcium Citrate
21 A Randomized, Prospective, Cross-Over Study of Calcitriol vs. Paricalcitol in the Treatment of Mineral and Bone Disease in Hemodialysis Patients Terminated NCT01725113 Phase 4 Calcitriol;Paricalcitol
22 A Prospective, Randomized, Open-Label Trial Investigating the Effect of 1 Alpha Hydroxy Vitamin D2 on the Development of Coronary Calcification in New ESRD Patients Using the 1-84/7-84 PTH Ratio to Determine Dosing Withdrawn NCT00502268 Phase 4 Doxercalciferol administration;Doxercalciferol administered by 1-84-7-84
23 Effect of Non-calcium Phosphate Binders Versus Calcium Based Binders on Chronic Kidney Disease -Mineral and Bone Disorder in Children on Regular Hemodialysis Unknown status NCT03202407 Phase 3 Calcium acetate and sevelamer hydrochloride
24 Changes in Biochemical and Vascular Parameters w/Lanthanum Carbonate & Calcium Acetate Therapy Compared to Dietary Intervention in Pts w/Stage 3 & 4 Chronic Kidney Disease & Abnormal Phosphorus Homeostasis: a Randomized Controlled Trial Unknown status NCT01357317 Phase 3 Phosphorus binder
25 A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia Completed NCT01833494 Phase 3 PA21
26 A Phase III Study of PA21 in Peritoneal Dialysis Patients With Hyperphosphatemia Completed NCT01852682 Phase 3 PA21
27 A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With Hyperphosphatemia Completed NCT01850641 Phase 3 PA21
28 A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia Completed NCT01850602 Phase 3 PA21;Sevelamer hydrochloride
29 Phase III Open Study of BAY 77 1931 (Lanthanum Carbonate) in Patients With Hyperphosphatemia Undergoing Continuous Ambulatory Peritoneal Dialysis (CAPD) Completed NCT01518387 Phase 3 Lanthanum Carbonate (BAY77-1931)
30 Phase III Double-blind Comparative Study of BAY 77 1931 (Lanthanum Carbonate) With a Calcium Carbonate in Patients With Hyperphosphatemia Undergoing Hemodialysis Completed NCT01514851 Phase 3 Lanthanum carbonate (BAY77-1931);Calcium carbonate
31 A Phase 3 Study in Patients With Chronic Kidney Disease (CKD) With Hyperphosphatemia on Peritoneal Dialysis Completed NCT01017276 Phase 3 ASP1585
32 A Phase 3, Multicenter, Open-label, Sevelamer Hydrochloride-controlled Study in Chronic Kidney Disease (CKD) Patients With Hyperphosphatemia on Hemodialysis Completed NCT01057407 Phase 3 ASP1585;Sevelamer hydrochloride
33 A Phase 3, Long-term Study in Patients With Chronic Kidney Disease (CKD) and Hyperphosphatemia on Hemodialysis Completed NCT00892749 Phase 3 ASP1585
34 ASP1585 Phase 3 Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis Completed NCT01742611 Phase 3 ASP1585
35 ASP1585 Phase 3 Randomized Double Blind Placebo-controlled Study in Chronic Kidney Disease (CKD) Patients With Hyperphosphatemia Not on Dialysis Completed NCT01742585 Phase 3 ASP1585;placebo
36 A Double-blind, Randomized, Placebo-controlled Multi-center Trial to Compare the Phosphate Lowering Efficacy of Different Doses of SBR759 to Placebo Completed NCT01069692 Phase 3 SBR759A;SBR759A;SBR759A;SBR759A;SBR759A
37 Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Lanthanum Carbonate 750 to 2250 mg in Patients With Chronic Kidney Disease Not on Dialysis Who Develop Hyperphosphatemia Completed NCT01110629 Phase 3 Fosrenol (Lanthanum Carbonate, BAY77-1931);Placebo
38 An Open-label, Long-term Extension Study of Lanthanum Carbonate 750 to 2,250 mg in Hyperphosphatemia in Patients With Chronic Kidney Disease Not on Dialysis (52 Weeks Extension From Study 14817) Completed NCT01187628 Phase 3 Fosrenol (Lanthanum Carbonate, BAY77-1931)
39 A Phase III, Multi-center, Open Label, Flexible Dose, Long Term Safety Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia Completed NCT00772382 Phase 3 MCI-196
40 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Definitive Phase III Study of the Effects of Ferric Citrate on Serum Phosphate in Subjects With End Stage Renal Disease Completed NCT01503736 Phase 3 ferric citrate;ferric citrate;ferric citrate
41 A Phase III, Randomised, Double-Blind, Multi-centre, Withdrawal Study Comparing MCI-196 Versus Placebo in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia Completed NCT00416520 Phase 3 MCI-196 (Colestilan(INN), Colestimide(JAN), CHOLEBINE®);Placebo;Another phosphate binder (Sevelamer)
42 A Phase III, Multi-centre, Double-blind, Randomised, Placebo-controlled Multiple Fixed-dose Study of MCI-196 Versus Placebo in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia (Incorporating Two Parallel High Dose Groups) Completed NCT00542386 Phase 3 MCI-196;Placebo
43 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-center, Withdrawal Study Comparing MCI-196 v.s Placebo Following A 12-Week Dose Titration Period With MCI-196 in Stage V Subjects on Dialysis With Hyperphosphatemia Completed NCT00506441 Phase 3 MCI-196;Placebo
44 A Randomized, Double Blind, Parallel Group Study For Assessing The Efficacy And Safety Of Renvela® Tablets For The Treatment Of Hyperphosphatemia In Patients With Chronic Kidney Disease Not On Dialysis Versus Placebo Completed NCT03001011 Phase 3 Placebo;Sevelamer Carbonate (GZ419831)
45 An 8-week, Multicenter, Randomized, Double-Blind, Parallel Group Study With a 4-week, Placebo-Controlled, Randomized Withdrawal Period to Evaluate the Efficacy, Safety, and Tolerability of Tenapanor to Treat Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD) Completed NCT02675998 Phase 3 Tenapanor;Placebo
46 A Phase III, Multicentre, Open Label, Flexible Dose, Long Term Safety Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia Completed NCT00542815 Phase 3 MCI-196;Another Phosphate binder (Sevelamer)
47 EPIC (Effect of PhosLo on Phosphorus Levels in Chronic Kidney Disease): A Prospective, Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Parallel Arm, Study of PhosLo on Phosphorus Levels in Subjects With Chronic Kidney Disease Completed NCT00211978 Phase 3 calcium acetate;placebo
48 A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) Following a Two-Week Washout Period Completed NCT01074125 Phase 3 ferric citrate
49 Study to Investigate Efficacy and Safety Equivalence of OsvaRen® Tablets and OsvaRen® Granules Completed NCT02027662 Phase 2, Phase 3 Osvaren Granules;Osvaren film-coated tablets
50 A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis Completed NCT01191255 Phase 3 ferric citrate, ca acetate, sevelamer carbonate, placebo

Search NIH Clinical Center for Hyperphosphatemia

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Aluminum hydroxide
Calcium acetate
Calcium carbonate
Ferric cation
Iron sucrose
Lanthanum carbonate
Sevelamer
Tetraferric tricitrate decahydrate

Cochrane evidence based reviews: hyperphosphatemia

Genetic Tests for Hyperphosphatemia

Genetic tests related to Hyperphosphatemia:

# Genetic test Affiliating Genes
1 Hyperphosphatemia 29

Anatomical Context for Hyperphosphatemia

MalaCards organs/tissues related to Hyperphosphatemia:

41
Kidney, Bone, Smooth Muscle, Colon, Liver, Heart, Endothelial

Publications for Hyperphosphatemia

Articles related to Hyperphosphatemia:

(show top 50) (show all 3143)
# Title Authors PMID Year
1
Targeted deletion of the Nesp55 DMR defines another Gnas imprinting control region and provides a mouse model of autosomal dominant PHP-Ib. 9 38
20427744 2010
2
The fibroblast growth factor 23: a new player in the field of cardiovascular, bone and renal disease. 9 38
20180772 2010
3
Recent advances in renal phosphate handling. 9 38
20177401 2010
4
Clinical variability of familial tumoral calcinosis caused by novel GALNT3 mutations. 9 38
20358599 2010
5
Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? 9 38
19965540 2010
6
Mapping of human autoantibody binding sites on the calcium-sensing receptor. 9 38
19580466 2010
7
In vivo genetic evidence for suppressing vascular and soft-tissue calcification through the reduction of serum phosphate levels, even in the presence of high serum calcium and 1,25-dihydroxyvitamin d levels. 9 38
20031638 2009
8
The journey from vitamin D-resistant rickets to the regulation of renal phosphate transport. 9 38
19808223 2009
9
Emerging topics in pediatric bone and mineral disorders 2008. 9 38
19615558 2009
10
[Chronic kidney disease (CKD) and bone. Vascular calcification in CKD]. 9 38
19329835 2009
11
[Disturbance of phosphorus metabolism in chronic kidney disease]. 9 38
19182354 2009
12
Vascular calcification in chronic kidney disease: pathogenesis and clinical implications. 9 38
19121777 2009
13
Impact of disturbances of calcium and phosphate metabolism on vascular calcification and clinical outcomes in patients with chronic kidney disease. 9 38
19295198 2009
14
An adolescent boy with thalassemia major presenting with bone pain, numbness, tetanic contractions and growth and pubertal delay: panhypopituitarism and combined vitamin D and parathyroid defects. 9 38
19337171 2008
15
Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. 9 38
18687639 2008
16
The mechanism of phosphorus as a cardiovascular risk factor in CKD. 9 38
18417722 2008
17
Bone mass does not correlate with the serum fibroblast growth factor 23 in hemodialysis patients. 9 38
17943081 2008
18
Fibroblast growth factor-23 is associated with parathyroid hormone and renal function in a population-based cohort of elderly men. 9 38
18166826 2008
19
Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis. 9 38
17914251 2008
20
Vitamin D receptor: key roles in bone mineral pathophysiology, molecular mechanism of action, and novel nutritional ligands. 9 38
18290715 2007
21
Regulatory mechanisms of circulating fibroblast growth factor 23 in parathyroid diseases. 9 38
17976083 2007
22
A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. 9 38
17710231 2007
23
Advantage of a low glycemic index and low phosphate diet on diabetic nephropathy and aging-related diseases. 9 38
17878688 2007
24
Emerging role of fibroblast growth factor 23 in a bone-kidney axis regulating systemic phosphate homeostasis and extracellular matrix mineralization. 9 38
17565275 2007
25
Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease. 9 38
17635819 2007
26
Fibroblast growth factor-23 (FGF23) in patients with transient hypoparathyroidism: its important role in serum phosphate regulation. 9 38
17464094 2007
27
Novel GALNT3 mutations causing hyperostosis-hyperphosphatemia syndrome result in low intact fibroblast growth factor 23 concentrations. 9 38
17311862 2007
28
Hyperostosis-hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23. 9 38
17129170 2007
29
Total parathyroidectomy with autotransplantation in patients with renal hyperparathyroidism: indications and surgical approach. 9 38
17178702 2006
30
Regulation of parathyroid function in chronic kidney disease (CKD). 9 38
17009074 2006
31
Osteopontin expression in vascular smooth muscle cells in patients with end-stage renal disease. 9 38
16817793 2006
32
[Familial tumoral calcinosis with hyperphosphatemia is heterogeneous and associated with mutations in GALNT3 or FGF-23]. 9 38
16733465 2006
33
Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats. 9 38
16395276 2006
34
FGF-23 and sFRP-4 in chronic kidney disease and post-renal transplantation. 9 38
16691036 2006
35
[Effects of intermittent treatment with sevelamer hydrochloride on parathyroid hyperplasia and vascular calcification in rats with chronic kidney disease]. 9 38
16272627 2005
36
[Fibroblast growth factor (FGF)-23 in patients with hypoparathyroidism]. 9 38
16272628 2005
37
Fibroblast growth factor 23 and its receptors. 9 38
16076372 2005
38
Fibroblast growth factor-23 in patients with Graves' disease before and after antithyroid therapy: its important role in serum phosphate regulation. 9 38
15827108 2005
39
Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. 9 38
15917335 2005
40
An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. 9 38
15590700 2005
41
Hyperphosphatemia in renal failure. 9 38
15627730 2005
42
Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. 9 38
15579309 2004
43
FGF-23 is elevated by chronic hyperphosphatemia. 9 38
15356053 2004
44
Management of calcium and bone abnormalities in hemodialysis patients. 9 38
15490408 2004
45
Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism. 9 38
15332221 2004
46
What have we learnt about the regulation of phosphate metabolism? 9 38
15199289 2004
47
FGF-23 in patients with end-stage renal disease on hemodialysis. 9 38
15086938 2004
48
[The present state of vitamin D supplementation or treatment among chronic dialysis patients]. 9 38
15576951 2004
49
Vitamin D receptor and analogs. 9 38
14730505 2004
50
Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. 9 38
14633152 2003

Variations for Hyperphosphatemia

Expression for Hyperphosphatemia

Search GEO for disease gene expression data for Hyperphosphatemia.

Pathways for Hyperphosphatemia

GO Terms for Hyperphosphatemia

Cellular components related to Hyperphosphatemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 apical plasma membrane GO:0016324 9.26 SLC34A1 KL GNAS CASR
2 perinuclear region of cytoplasm GO:0048471 9.02 STX16 SLC34A1 PHEX GNAS GALNT3

Biological processes related to Hyperphosphatemia according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 cellular calcium ion homeostasis GO:0006874 9.73 VDR PTH GCM2 CASR
2 ossification GO:0001503 9.71 SLC34A1 RUNX2 MGP CASR
3 fibroblast growth factor receptor signaling pathway GO:0008543 9.7 KL GALNT3 FGF23
4 embryonic cranial skeleton morphogenesis GO:0048701 9.62 RUNX2 GNAS
5 positive regulation of bone mineralization GO:0030501 9.61 PTH KL
6 response to cadmium ion GO:0046686 9.61 SLC34A1 PTH
7 endochondral ossification GO:0001958 9.6 RUNX2 GNAS
8 regulation of bone mineralization GO:0030500 9.59 MGP FGF23
9 response to lead ion GO:0010288 9.58 SLC34A1 PTH
10 response to vitamin D GO:0033280 9.58 PTH PHEX
11 energy reserve metabolic process GO:0006112 9.57 KL GNAS
12 vitamin D metabolic process GO:0042359 9.56 VDR FGF23
13 response to magnesium ion GO:0032026 9.55 SLC34A1 FGF23
14 skeletal system development GO:0001501 9.55 VDR RUNX2 PTH PHEX GNAS
15 response to growth hormone GO:0060416 9.54 SLC34A1 PHEX
16 cellular response to vitamin D GO:0071305 9.54 PHEX FGF23 CASR
17 response to fibroblast growth factor GO:0071774 9.51 PTH CASR
18 cellular response to parathyroid hormone stimulus GO:0071374 9.5 SLC34A1 PHEX FGF23
19 positive regulation of MAPKKK cascade by fibroblast growth factor receptor signaling pathway GO:0090080 9.49 KL FGF23
20 response to sodium phosphate GO:1904383 9.48 PHEX FGF23
21 positive regulation of vitamin D 24-hydroxylase activity GO:0010980 9.46 VDR FGF23
22 cellular phosphate ion homeostasis GO:0030643 9.43 SLC34A1 GCM2 FGF23
23 bone mineralization GO:0030282 9.32 PHEX
24 phosphate ion homeostasis GO:0055062 9.13 SLC34A1 PTH FGF23
25 response to parathyroid hormone GO:0071107 8.8 SLC34A1 PTH GNAS

Molecular functions related to Hyperphosphatemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 fibroblast growth factor receptor binding GO:0005104 8.96 KL FGF23
2 vitamin D binding GO:0005499 8.62 VDR KL

Sources for Hyperphosphatemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....